CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 1.97% at $64.76. This change lagged the S&P 500's daily gain of 0.4%. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.24%. The company's stock has climbed by 41.46% in the past month, exceeding the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61%.Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company is forecasted to report an EPS of -$1.47, showcasing a 1.34% upward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $6.58 million, up 1165.77% from the year-ago period. CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.61 per share and revenue of $41.42 million. These results would represent year-over-year changes of -29.26% and +11%, respectively. Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 1.38% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG currently has a Zacks Rank of #4 (Sell). The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Should You Invest in CRISPR Therapeutics AG (CRSP)?Before you invest in CRISPR Therapeutics AG (CRSP), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks